Subtopic Deep Dive
Non-alcoholic Fatty Liver Disease
Research Guide
What is Non-alcoholic Fatty Liver Disease?
Non-alcoholic Fatty Liver Disease (NAFLD) is a chronic liver condition characterized by hepatic steatosis in individuals without significant alcohol consumption, progressing from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis.
NAFLD affects 25-30% of the global population and links to obesity, type 2 diabetes, and metabolic syndrome. Research focuses on non-invasive diagnostics like the NAFLD Fibrosis Score and epidemiological modeling of disease burden. Over 30,000 papers exist on NAFLD, with key guidelines from Chalasani et al. (2017, 7022 citations) and Angulo et al. (2007, 3108 citations).
Why It Matters
NAFLD drives the rise in chronic liver disease, cirrhosis, and hepatocellular carcinoma amid obesity epidemics, as modeled by Estes et al. (2017, 2288 citations) predicting exponential burden increases. It elevates cardiovascular and extrahepatic mortality risks per fibrosis stage, shown in Dulai et al. (2017, 1780 citations) meta-analysis. Global perspectives by Younossi (2018, 2077 citations) highlight needs for diagnostics and therapies, with new nomenclature from Rinella et al. (2023, 2312 citations) aiding unified research efforts.
Key Research Challenges
Non-invasive Fibrosis Assessment
Distinguishing advanced fibrosis without biopsy remains challenging despite scores like NAFLD Fibrosis Score (Angulo et al., 2007, 3108 citations). Comparative studies show variable accuracy of markers (Shah et al., 2009, 1452 citations). Ultrasound meta-analysis confirms moderate reliability for steatosis detection (Hernáez et al., 2011, 1511 citations).
Disease Progression Modeling
Predicting progression from steatosis to NASH and cirrhosis requires better longitudinal models. Estes et al. (2017, 2288 citations) demonstrate exponential burden growth. Mortality risks escalate by fibrosis stage (Dulai et al., 2017, 1780 citations).
Therapeutic Target Identification
Lack of approved therapies persists despite guidelines (Chalasani et al., 2017, 7022 citations). Multisystem impacts complicate interventions (Byrne and Targher, 2015, 2976 citations). Nomenclature shifts aim to refocus drug development (Rinella et al., 2023, 2312 citations).
Essential Papers
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani, Zobair M. Younossi, Joel E. Lavine et al. · 2017 · Hepatology · 7.0K citations
This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care. A “Guidance” document is different from a “Guideline.” Guidelines are develope...
The NAFLD fibrosis score
Paul Angulo, Jason M. Hui, Giulio Marchesini et al. · 2007 · Hepatology · 3.1K citations
a simple scoring system accurately separates patients with NAFLD with and without advanced fibrosis, rendering liver biopsy for identification of advanced fibrosis unnecessary in a substantial prop...
NAFLD: A multisystem disease
Christopher D. Byrne, Giovanni Targher · 2015 · Journal of Hepatology · 3.0K citations
Non-alcoholic fatty liver disease
Elizabeth E. Powell, Vincent Wai‐Sun Wong, Mary E. Rinella · 2021 · The Lancet · 2.5K citations
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu et al. · 2023 · Journal of Hepatology · 2.3K citations
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Chris Estes, Homie Razavi, Rohit Loomba et al. · 2017 · Hepatology · 2.3K citations
Nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) are highly prevalent in the United States, where they are a growing cause of cirrhosis and hepatocellular ...
Non-alcoholic fatty liver disease – A global public health perspective
Zobair M. Younossi · 2018 · Journal of Hepatology · 2.1K citations
Reading Guide
Foundational Papers
Start with Angulo et al. (2007, 3108 citations) for NAFLD Fibrosis Score as core diagnostic tool; Chalasani et al. (2012, 1757 citations) for early guidelines establishing management standards.
Recent Advances
Study Rinella et al. (2023, 2312 citations) for nomenclature consensus; Powell et al. (2021, 2499 citations) for updated epidemiology and diagnostics.
Core Methods
Core techniques include NAFLD Fibrosis Score (Angulo et al., 2007), ultrasound meta-analysis (Hernáez et al., 2011), and epidemiological modeling (Estes et al., 2017).
How PapersFlow Helps You Research Non-alcoholic Fatty Liver Disease
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map NAFLD literature from Chalasani et al. (2017, 7022 citations), revealing 7000+ citing works on diagnostics. exaSearch uncovers global burden papers like Younossi (2018), while findSimilarPapers links fibrosis scores to progression models.
Analyze & Verify
Analysis Agent employs readPaperContent on Angulo et al. (2007) to extract NAFLD Fibrosis Score equations, then runPythonAnalysis with pandas to recompute scores on patient datasets for verification. verifyResponse (CoVe) and GRADE grading assess guideline strength in Chalasani et al. (2017), flagging low-evidence recommendations.
Synthesize & Write
Synthesis Agent detects gaps in fibrosis diagnostics via contradiction flagging across Shah et al. (2009) and Hernáez et al. (2011). Writing Agent uses latexEditText, latexSyncCitations for guideline summaries, and latexCompile to generate review manuscripts with exportMermaid diagrams of progression pathways.
Use Cases
"Recompute NAFLD Fibrosis Scores on a sample dataset to validate against biopsy results"
Research Agent → searchPapers('NAFLD Fibrosis Score') → Analysis Agent → readPaperContent(Angulo 2007) → runPythonAnalysis(pandas score calculator) → matplotlib plot of score distributions vs fibrosis stages.
"Draft a LaTeX review on NAFLD nomenclature changes with citations"
Research Agent → citationGraph(Rinella 2023) → Synthesis Agent → gap detection → Writing Agent → latexEditText(structured sections) → latexSyncCitations(10 papers) → latexCompile(PDF review with figures).
"Find GitHub repos implementing NAFLD risk models from recent papers"
Research Agent → searchPapers('NAFLD progression model') → Code Discovery → paperExtractUrls(Estes 2017) → paperFindGithubRepo → githubRepoInspect(code for burden simulations).
Automated Workflows
Deep Research workflow conducts systematic reviews by chaining searchPapers(50+ NAFLD papers) → citationGraph → GRADE grading, producing structured reports on fibrosis biomarkers. DeepScan applies 7-step analysis with CoVe checkpoints to verify progression models from Estes et al. (2017). Theorizer generates hypotheses on multisystem links by synthesizing Byrne and Targher (2015) with gap detection.
Frequently Asked Questions
What defines NAFLD?
NAFLD is hepatic fat accumulation without excess alcohol, progressing to NASH (Powell et al., 2021, The Lancet).
What are key diagnostic methods?
NAFLD Fibrosis Score non-invasively stages fibrosis (Angulo et al., 2007, 3108 citations); ultrasound detects steatosis reliably (Hernáez et al., 2011, 1511 citations).
What are landmark NAFLD papers?
Chalasani et al. (2017, Hepatology, 7022 citations) provides AASLD guidance; Angulo et al. (2007, 3108 citations) introduces fibrosis score.
What open problems exist in NAFLD?
Therapy development lags despite burden growth (Estes et al., 2017); fibrosis staging needs better non-invasive tools (Dulai et al., 2017).
Research Liver Disease and Transplantation with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Non-alcoholic Fatty Liver Disease with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
Part of the Liver Disease and Transplantation Research Guide